Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.4 USD | -2.58% | +14.48% | -19.24% |
May. 02 | CUREVAC : A missed opportunity | |
Apr. 26 | UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the past twelve months, EPS forecast has been revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-19.24% | 782M | D+ | ||
+41.79% | 50.93B | B- | ||
-0.56% | 42.12B | B | ||
+49.62% | 42.05B | A | ||
-7.20% | 29.18B | C | ||
+12.59% | 26.02B | B- | ||
-21.51% | 18.9B | B | ||
+6.92% | 13.21B | B+ | ||
+24.91% | 12.17B | B+ | ||
+29.60% | 12.16B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CVAC Stock
- Ratings CureVac N.V.